Literature DB >> 24713004

Historical epidemiology of hepatitis C virus (HCV) in selected countries.

P Bruggmann1, T Berg, A L H Øvrehus, C Moreno, C E Brandão Mello, F Roudot-Thoraval, R T Marinho, M Sherman, S D Ryder, J Sperl, U Akarca, I Balık, F Bihl, M Bilodeau, A J Blasco, M Buti, F Calinas, J L Calleja, H Cheinquer, P B Christensen, M Clausen, H S M Coelho, M Cornberg, M E Cramp, G J Dore, W Doss, A S Duberg, M H El-Sayed, G Ergör, G Esmat, C Estes, K Falconer, J Félix, M L G Ferraz, P R Ferreira, S Frankova, J García-Samaniego, J Gerstoft, J A Giria, F L Gonçales, E Gower, M Gschwantler, M Guimarães Pessôa, C Hézode, H Hofer, P Husa, R Idilman, M Kåberg, K D E Kaita, A Kautz, S Kaymakoglu, M Krajden, H Krarup, W Laleman, D Lavanchy, P Lázaro, P Marotta, S Mauss, M C Mendes Correa, B Müllhaupt, R P Myers, F Negro, V Nemecek, N Örmeci, J Parkes, K M Peltekian, A Ramji, H Razavi, N Reis, S K Roberts, W M Rosenberg, R Sarmento-Castro, C Sarrazin, D Semela, G E Shiha, W Sievert, P Stärkel, R E Stauber, A J Thompson, P Urbanek, I van Thiel, H Van Vlierberghe, D Vandijck, W Vogel, I Waked, H Wedemeyer, N Weis, J Wiegand, A Yosry, A Zekry, P Van Damme, S Aleman, S J Hindman.   

Abstract

Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  HCV; diagnosis; disease burden; epidemiology; hepatitis C; incidence; mortality; prevalence; treatment

Mesh:

Substances:

Year:  2014        PMID: 24713004     DOI: 10.1111/jvh.12247

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  75 in total

1.  High seroprevalence of HCV in the Abruzzo Region, Italy: results on a large sample from opt-out pre-surgical screening.

Authors:  Ennio Polilli; Monica Tontodonati; Maria Elena Flacco; Tamara Ursini; Palmira Striani; Dante Di Giammartino; Maurizio Paoloni; Luigi Vallarola; Gabriella Lucidi Pressanti; Giorgia Fragassi; Patrizia Accorsi; Lamberto Manzoli; Giustino Parruti
Journal:  Infection       Date:  2015-09-12       Impact factor: 3.553

Review 2.  Treatment Options in Hepatitis C.

Authors:  Stefan Zeuzem
Journal:  Dtsch Arztebl Int       Date:  2017-01-09       Impact factor: 5.594

Review 3.  Global epidemiology and burden of HCV infection and HCV-related disease.

Authors:  Aaron P Thrift; Hashem B El-Serag; Fasiha Kanwal
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-12-07       Impact factor: 46.802

Review 4.  Genotype 3 Infection: The Last Stand of Hepatitis C Virus.

Authors:  Austin Chan; Keyur Patel; Susanna Naggie
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

Review 5.  Injecting drug use: A vector for the introduction of new hepatitis C virus genotypes.

Authors:  Simona Ruta; Costin Cernescu
Journal:  World J Gastroenterol       Date:  2015-10-14       Impact factor: 5.742

6.  Chronic hepatitis C virus (HCV) burden in Rhode Island: modelling treatment scale-up and elimination.

Authors:  A I Soipe; H Razavi; D Razavi-Shearer; O Galárraga; L E Taylor; B D L Marshall
Journal:  Epidemiol Infect       Date:  2016-08-05       Impact factor: 2.451

Review 7.  Hepatitis C genotype 3 disease.

Authors:  Sarah Kattakuzhy; Rachel Levy; Elana Rosenthal; Lydia Tang; Eleanor Wilson; Shyam Kottilil
Journal:  Hepatol Int       Date:  2016-06-21       Impact factor: 6.047

Review 8.  Direct-acting antiviral agents for HCV infection affecting people who inject drugs.

Authors:  Jason Grebely; Behzad Hajarizadeh; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2017-08-23       Impact factor: 46.802

Review 9.  Hepatitis C virus relies on lipoproteins for its life cycle.

Authors:  Germana Grassi; Giorgia Di Caprio; Gian Maria Fimia; Giuseppe Ippolito; Marco Tripodi; Tonino Alonzi
Journal:  World J Gastroenterol       Date:  2016-02-14       Impact factor: 5.742

Review 10.  Hepatitis C elimination among people who inject drugs: Challenges and recommendations for action within a health systems framework.

Authors:  Emma Day; Margaret Hellard; Carla Treloar; Julie Bruneau; Natasha K Martin; Anne Øvrehus; Olav Dalgard; Andrew Lloyd; John Dillon; Matt Hickman; Jude Byrne; Alain Litwin; Mojca Maticic; Philip Bruggmann; Havard Midgard; Brianna Norton; Stacey Trooskin; Jeffrey V Lazarus; Jason Grebely
Journal:  Liver Int       Date:  2018-09-22       Impact factor: 5.828

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.